Does a transfer-learning-based DenseNet121 MRI model improve the prediction of breast cancer recurrence in patients undergoing NAT compared to standard clinical factors?
433 breast cancer patients who underwent neoadjuvant therapy (NAT) from the multicenter MAMA-MIA dataset (115 with recurrence events, 318 recurrence-free)
Transfer-learning framework based on DenseNet121 pretrained on ImageNet using pretreatment DCE-MRI exams
Baseline prognostic model based on established clinical factors HR and HER2
Breast cancer recurrence at 3 and 5 year horizons (evaluated using Harrell’s C-index and time-dependent AUCs)
A transfer-learning MRI model provides added value beyond standard clinical factors for predicting 3- and 5-year recurrence in breast cancer patients.
Abstract Background: MRI features have demonstrated prognostic value in predicting future breast cancer recurrence. However, deep learning studies remain limited particularly those evaluating performance across tumor subtypes and different time horizons in large multicenter datasets. Materials and Methods: We used pretreatment DCE-MRI exams from the multicenter MAMA-MIA dataset (433 breast cancer patients who underwent NAT; 115 with recurrence events, 318 recurrence-free) to evaluate a transfer-learning framework based on DenseNet121 pretrained on ImageNet. Middle tumor-containing slices were bias-field corrected, resampled, cropped to the tumor regions, and resized to 224×224 pixels. The top 10% of DenseNet121 layers were unfrozen for model fine-tuning for recurrence prediction. Five-fold stratified cross-validation preserved site distribution across data splits. Model performance was evaluated using Harrell’s C-index and time-dependent AUCs at 3 and 5 year horizons. Correlated C-indices were compared using the two-sided Kang et al. test. We also assessed the added value by our deep-learning risk score to a baseline prognostic model based on the established clinical factors HR and HER2. Model performance was also assessed across tumor subtypes. Results: Our deep learning model achieved a C-index of 0.67±0.03 with 3 and 5 year AUCs of 0.69±0.04 and 0.67±0.10, respectively. Adding our deep-learning risk score to the baseline model significantly improved performance from 0.64 to 0.71 (p=0.007). Subtype-specific evaluations (Table 1) showed variable performances with the highest performance in HER2-pure and TNBC patients. Conclusion: Our findings highlight the potential of a transfer-learning-based DenseNet121 MRI model to predict 3 and 5 year recurrences in breast cancer patients, providing added value beyond standard clinical factors. Future optimizations will aim at improving subtype-specific performance in large multicenter datasets. Citation Format: Kanika Bhalla, Adrian Sanchez, José Marcio Luna, Tabassum Ahmad, Debbie L. Bennett, Andrew A. Davis, Aimilia Gastounioti, . Assessing the risk of breast cancer recurrence with pre-treatment MRI: A transfer learning study on multicenter data abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2785.
Building similarity graph...
Analyzing shared references across papers
Loading...
Kanika Bhalla
Adrian A. Sánchez
José Marcio Luna
Cancer Research
Washington University in St. Louis
Building similarity graph...
Analyzing shared references across papers
Loading...
Bhalla et al. (Fri,) studied this question.
www.synapsesocial.com/papers/69d1fde4a79560c99a0a438a — DOI: https://doi.org/10.1158/1538-7445.am2026-2785
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: